True Restriction in Diffusion-Weighted Imaging in a Mistreated Patient With Phenylketonuria.


Journal

The neurologist
ISSN: 2331-2637
Titre abrégé: Neurologist
Pays: United States
ID NLM: 9503763

Informations de publication

Date de publication:
30 Dec 2020
Historique:
entrez: 4 1 2021
pubmed: 5 1 2021
medline: 2 10 2021
Statut: epublish

Résumé

Phenylketonuria (PKU) is the most common inborn error of amino acid metabolism and causes neurological manifestations because of excessive accumulation of phenylalanine (PHE). It can also affect adult patients who discontinue their treatment, even if they had been under adequate metabolic control during childhood. For that reason, it is recommended that PKU treatment should be continued throughout life and target PHE levels for adult patients should range between 120 and 600 μmol/L. The authors present an adult patient with PKU who discontinued treatment and developed cognitive dysfunction because of high blood levels of PHE. Brain magnetic resonance imaging (MRI) of the patient was characteristic for PKU, presenting periventricular and callosal white matter hyperintensities in T2 and fluid-attenuated inversion recovery sequences, which were additionally associated with true restriction in diffusion-weighted imaging sequence, a far less recognized PKU neuroimaging feature. Cognitive dysfunction and psychiatric disorders can be present in adult patients with PKU who discontinue treatment and have poor PHE metabolic control. The presence of white matter hyperintensities in T2 and fluid-attenuated inversion recovery MRI-sequences is a well-described neuroimaging feature of PKU, but diffusion-weighted imaging sequence may also be reliable in detecting brain lesions in patients with PKU. PKU lesions should be considered in the differential diagnosis of true diffusion restriction in brain MRI of patients with PKU history or those who might have escaped newborn screening diagnosis but present neurocognitive dysfunction. Appropriate treatment for the management of PKU should be initiated for the reversal of the clinical and neuroimaging findings.

Identifiants

pubmed: 33394907
doi: 10.1097/NRL.0000000000000295
pii: 00127893-202101000-00005
doi:

Substances chimiques

Phenylalanine 47E5O17Y3R

Types de publication

Case Reports Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

20-21

Informations de copyright

Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.

Déclaration de conflit d'intérêts

The authors declare no conflict of interest.

Références

Blau N, van Spronsen FJ, Levy HL. Phenylketonuria. Lancet. 2010;376:1417–1427.
van Wegberg AMJ, MacDonald A, Ahring K, et al. The complete European guidelines on phenylketonuria: diagnosis and treatment. Orphanet J Rare Dis. 2017;12:162.
Enns GM, Koch R, Brumm V, et al. Suboptimal outcomes in patients with PKU treated early with diet alone: revisiting the evidence. Mol Genet Metab. 2010;101:99–109.
Anderson PJ, Leuzzi V. White matter pathology in phenylketonuria. Mol Genet Metab. 2010;99(suppl 1):S3–S9.
Bilder DA, Noel JK, Baker ER, et al. Systematic review and meta-analysis of neuropsychiatric symptoms and executive functioning in adults with phenylketonuria. Dev Neuropsychol. 2016;41:245–260.
Hofman DL, Champ CL, Lawton CL, et al. A systematic review of cognitive functioning in early treated adults with phenylketonuria. Orphanet J Rare Dis. 2018;13:150.
Cazzorla C, Bensi G, Biasucci G, et al. Living with phenylketonuria in adulthood: The PKU ATTITUDE study. Mol Genet Metab Rep. 2018;16:39–45.
Macdonald A, Nanuwa K, Parkes L, et al. Retrospective, observational data collection of the treatment of phenylketonuria in the UK, and associated clinical and health outcomes. Curr Med Res Opin. 2011;27:1211–1222.
Thompson AJ, Tillotson S, Smith I, et al. Brain MRI changes in phenylketonuria. Associations with dietary status. Brain. 1993;116 (Pt 4):811–821.
Cleary MA, Walter JH, Wraith JE, et al. Magnetic resonance imaging of the brain in phenylketonuria. Lancet. 1994;344:87–90.
Phillips MD, McGraw P, Lowe MJ, et al. Diffusion-weighted imaging of white matter abnormalities in patients with phenylketonuria. AJNR Am J Neuroradiol. 2001;22:1583–1586.
Kono K, Okano Y, Nakayama K, et al. Diffusion-weighted MR imaging in patients with phenylketonuria: relationship between serum phenylalanine levels and ADC values in cerebral white matter. Radiology. 2005;236:630–636.
Manara R, Burlina AP, Citton V, et al. Brain MRI diffusion-weighted imaging in patients with classical phenylketonuria. Neuroradiology. 2009;51:803–812.
Finelli PF. Diagnostic approach to restricted-diffusion patterns on MR imaging. Neurol Clin Pract. 2012;2:287–293.
Schaefer PW, Grant PE, Gonzalez RG. Diffusion-weighted MR imaging of the brain. Radiology. 2000;217:331–345.

Auteurs

Lina Palaiodimou (L)

Second Department of Neurology, National and Kapodistrian University of Athens, School of Medicine.

Christina Zompola (C)

Second Department of Neurology, National and Kapodistrian University of Athens, School of Medicine.

Stefanos Lachanis (S)

Iatropolis Magnetic Resonance Diagnostic Centre.

Varvara Mylona (V)

Department of Nutrition and Dietetics, "Attikon" University Hospital.

Aikaterini Theodorou (A)

Second Department of Neurology, National and Kapodistrian University of Athens, School of Medicine.

Georgia Papagiannopoulou (G)

Second Department of Neurology, National and Kapodistrian University of Athens, School of Medicine.

Vasiliki Kotsali-Peteinelli (V)

Second Department of Neurology, National and Kapodistrian University of Athens, School of Medicine.

Aikaterini Foska (A)

Second Department of Neurology, National and Kapodistrian University of Athens, School of Medicine.

Arezina Kasti (A)

Department of Nutrition and Dietetics, "Attikon" University Hospital.

Anastasia Skouma (A)

Department of Νewborn Screening, Institute of Child Health, Athens, Greece.

Georgios Tsivgoulis (G)

Second Department of Neurology, National and Kapodistrian University of Athens, School of Medicine.
Department of Neurology, The University of Tennessee Health Science Center, Memphis, TN.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH